Results 111 to 120 of about 137,029 (384)

The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial

Pediatric Rheumatology Online Journal, 2010
Background We evaluated the effect of infliximab on markers of inflammation in patients with juvenile idiopathic arthritis (JIA). Methods In this randomized, placebo-controlled substudy, 122 patients with JIA received infliximab 3 mg/kg + methotrexate ...
Gerloni Valeria, Fasth Anders, Baildam Eileen, Apaz Maria T, Gattorno Marco, Espada Graciela, Woo Patricia, Cuttica Ruben, Petty Ross, Martini Alberto, Lovell Daniel J, Marini Joseph C, Wagner Carrie, Visvanathan Sudha, Lahdenne Pekka, Quartier Pierre, Saurenmann Rotraud, Travers Suzanne, Mendelsohn Alan, Xu Stephen, Giannini Edward H, Ruperto Nicolino   +21 more
doaj   +1 more source

Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta [PDF]

, 2007
The induction of regulatory T (T reg) cells holds considerable potential as a treatment for autoimmune diseases. We have previously shown that CD4(+)CD25(hi) T reg cells isolated from patients with active rheumatoid arthritis (RA) have a defect in their ...
Ehrenstein, MR, Mauri, C, Nadkarni, S
core  

Aseptic meningitis in a patient taking etanercept for rheumatoid arthritis: a case report [PDF]

, 2008
Background \ud We report a case of a 53 year old lady recently commenced on etanercept, an anti-TNF (tumour necrosis factor) therapy for rheumatoid arthritis presenting with \ud confusion, pyrexia and an erythematous rash. \ud \ud Case presentation \ud
AP Cairns, B Killingley, DJ Lovell, J Listing, JR Curtis, Julia Flint, M Chávez-López, Matthew J Booker, ME Weinblatt, NR Slifman, P Pagliano, R Quispel, Shanmugam Saravana, WG Dixon   +13 more
core   +4 more sources

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience

Inflammatory Bowel Diseases, 2018
Background The purpose of this study was to compare the long-term safety of infliximab and nonbiologic agents as Crohn’s disease (CD) therapy. Methods Patients with CD were prospectively evaluated in this large, observational registry.
G. Lichtenstein, B. Feagan, R. Cohen, B. Salzberg, M. Safdi, J. Popp, W. Langholff, W. Sandborn   +7 more
semanticscholar   +1 more source

Oral vancomycin solution is superior to capsule in inducing clinical biomarker and endoscopic remission in children with atypical ulcerative colitis

British Journal of Clinical Pharmacology, EarlyView.
Aims Atypical colitis (presenting reverse gradient colitis, backwash ileitis or rectal sparing) is associated with primary sclerosing cholangitis–ulcerative colitis (PSC). Oral vancomycin has been used to manage paediatric atypical colitis with/without confirmed PSC. Different preparations had shown different efficacy.
Laura Räisänen, Fariha Balouch, Claire Reilly, Christopher Burgess, Peter Lewindon   +4 more
wiley   +1 more source

Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure

Gut and Liver
Background/Aims: Studies on elective switching to the subcutaneous (SC) formulation of infliximab revealed comparable efficacy and safety and higher infliximab level than those exhibited by intravenous (IV) infliximab.
June Hwa Bae, Jung-Bin Park, Ji Eun Baek, Seung Wook Hong, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sung Wook Hwang   +10 more
doaj   +1 more source

Biologic treatments in rheumatoid arthritis and juvenile idiopathic arthritis [PDF]

, 2006
A number of biological approaches to the management of inflammtory arthropathies have been explored. These include the development of IL-1 receptor antagonists and TNF antagonists. Four biological agents are currently marketed in Europe.
Borg, Andrew A.
core  

Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease

Journal of Crohn's & Colitis, 2018
Background and Aims Reactive testing has emerged as the new standard of care for managing loss of response to infliximab in inflammatory bowel disease [IBD].
K. Papamichael, Ravy K. Vajravelu, B. Vaughn, M. Osterman, A. Cheifetz   +4 more
semanticscholar   +1 more source

The prevalence of polypharmacy increases with age among patients with inflammatory bowel disease: A nationwide cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims Polypharmacy is common in adult patients with inflammatory bowel disease (IBD). This study aims to quantify medication prescriptions and estimate the risk of polypharmacy over time in older adults with IBD. Methods In a nationwide cohort of adult incident IBD patients from 1 April 1996, to 31 December 2019, we examined medication prescriptions ...
Ken Lund, Jesper Ryg, Torben Knudsen, Jens Kjeldsen, Jan Nielsen, Sonia Friedman, Jimmy K. Limdi, Bente Mertz Nørgård   +7 more
wiley   +1 more source

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events

Drug Design, Development and Therapy, 2019
Psoriasis is a chronic immune-mediated skin disease affecting multiple systems, and tumor necrosis factor-α (TNF-α) plays a significant role in the initiation and progression of the disease process.
Smriti Subedi, Yu Gong, Youdong Chen, Yuling Shi   +3 more
semanticscholar   +1 more source